TOP - September 2011 Vol 4, No 6
Oncology pharmacists have a new tool for helping them better treat their patients. The Association of Community Cancer Centers (ACCC) has released a new publication, “The Practical Cancer Pharmacy,” designed to help hospital cancer pharmacy and financial teams move past the short-term orientation of considering only cost when deciding which drugs to purchase.
For patients with non–small-cell lung cancer (NSCLC), concurrent delivery of once-daily chemotherapy and thoracic radiotherapy produced significantly higher 5-year survival in a phase 3 trial (Curran WJ Jr, et al. J Natl Cancer Inst. September 8, 2011. Epub ahead of print).
With the high survival rate of children with acute lymphoblastic leukemia (ALL), there is interest in extending pediatric regimens to adult populations with the disease. Choosing the right therapy for the right patient, however, remains challenging, according to Daniel J. DeAngelo, MD, at the National Comprehensive Cancer Network (NCCN) 6th Annual Congress: Hematologic Malignancies.
The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris; Seattle Genetics) to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
With brentuximab, an antibody-drug conjugate, the antibody directs the drug to the target CD30. The agent is to be used in patients with HL whose disease has progressed after autologous stem-cell transplant or, for those who cannot receive a transplant, after 2 lines of chemotherapy. Brentuximab also may be used in patients with ALCL whose disease has progressed after 1 line of chemotherapy.
Results 1 - 10 of 20